Compare BioNano Genomics Inc (BNGO) vs MINISO Group Holding Ltd (MNSO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BioNano Genomics Inc vs MINISO Group Holding Ltd — how do they compare? BioNano Genomics Inc trades at $1.2 (market cap $13.66M), while MINISO Group Holding Ltd trades at $11.89 (market cap $3.62B). The key difference: MINISO Group Holding Ltd is far larger — about 265× BioNano Genomics Inc's market cap, and MINISO Group Holding Ltd pays a 5.53% dividend while BioNano Genomics Inc pays none. Which is the better fit depends on your goals.
| BNGO | MNSO | |
|---|---|---|
Market Cap | $13.66M | $3.62B |
Sector | Health | Technology |
52-Week High | $4.92 | $26.63 |
52-Week Low | $1.06 | $11.30 |
Enterprise Value | $16.26M | $4.29B |
Dividend Yield | — | 5.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BNGO trades at $1.19, up 2.59% today, with bullish technical signals from moving averages. The company shows improving financials with revenue stabilizing around $29M annually and narrowing losses, though it remains unprofitable. Recent earnings have consistently beaten expectations, and analyst sentiment is positive with 57% buy ratings. Key developments include debt retirement and scientific publications highlighting optical genome mapping adoption.
The outlook is cautiously optimistic given improving fundamentals and positive analyst coverage, but significant risks remain due to persistent losses and negative cash flow. Investment opportunity lies in the company's technology adoption growth, while primary risks include profitability challenges and competitive pressures in the genomics space.
MNSO trades at $11.895, down 4.99% in the last session amid a neutral technical outlook. Recent earnings show volatility with a Q1 2026 beat but Q3 and Q4 2025 misses, while fundamentals reveal solid revenue growth to $21.44 billion in 2025 and a net income margin of 8.98%. The company announced a $2 billion share repurchase program in June 2026, signaling confidence.
The stock presents a mixed outlook: valuation ratios like P/E of 12.16 appear reasonable, and analyst consensus is 75% buy, but risks include margin pressure from SG&A growth and competitive retail dynamics. Near-term price action hinges on Q2 2026 earnings delivery against expectations of $0.2754 EPS.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BioNano Genomics Inc
Bionano Genomics Inc is a life sciences instrumentation company in the genome analysis space. It is engaged in the development and marketing of the Saphyr system, a platform for ultra-sensitive and ultra-specific structural variation detection that enables researchers and clinicians to accelerate the search for new diagnostics and therapeutic targets and to streamline the study of changes in chromosomes.
Read more on BNGO →About MINISO Group Holding Ltd
MINISO Group Holding Ltd is a global lifestyle product retailer known for its aesthetically pleasing, high-quality, and low-cost goods. The company operates a network of branded stores worldwide, offering a diverse range of merchandise, including household goods, cosmetics, toys, and digital accessories. MINISO's business model emphasizes rapid product iteration, efficient supply chain management, and a joint venture and franchise partner network to facilitate its global expansion.
Read more on MNSO →
